|
|
|
|
| LEADER |
02755nam a2200469 4500 |
| 001 |
978-3-319-78238-6 |
| 003 |
DE-He213 |
| 005 |
20191023172013.0 |
| 007 |
cr nn 008mamaa |
| 008 |
180424s2018 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783319782386
|9 978-3-319-78238-6
|
| 024 |
7 |
|
|a 10.1007/978-3-319-78238-6
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a RC261-271
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 072 |
|
7 |
|a MJCL
|2 thema
|
| 082 |
0 |
4 |
|a 614.5999
|2 23
|
| 245 |
1 |
0 |
|a Resistance to Ibritumomab in Lymphoma
|h [electronic resource] /
|c edited by Makoto Hosono, Jean-François Chatal.
|
| 250 |
|
|
|a 1st ed. 2018.
|
| 264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2018.
|
| 300 |
|
|
|a XIII, 158 p. 18 illus., 14 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Resistance to Targeted Anti-Cancer Therapeutics,
|x 2196-5501 ;
|v 18
|
| 505 |
0 |
|
|a Clinical Use and Efficacy of Ibritumomab in B-cell Lymphoma -- Biology and Pathology of B-cell lymphoma -- Resistance to Y-90 Ibritumomab Tiuxetan Therapy -- Features of Ibritumomab as Radionuclide Therapy -- Radiological Evaluation of Response and Resistance of Ibritumomab -- Characteristics of Ibritumomab as Radionuclide Therapy Agent -- Resistance and Heterogeneity of Intratumoral Antibody Distribution -- Radiation Dosimetry in Ibritumomab Therapy -- Combining RAIT and immune-based therapies to overcome resistance in cancer? -- Prospects for enhancing efficacy of radioimmunotherapy -- Index.
|
| 520 |
|
|
|a This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
1 |
4 |
|a Cancer Research.
|0 http://scigraph.springernature.com/things/product-market-codes/B11001
|
| 700 |
1 |
|
|a Hosono, Makoto.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
| 700 |
1 |
|
|a Chatal, Jean-François.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319782379
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319782393
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783030086527
|
| 830 |
|
0 |
|a Resistance to Targeted Anti-Cancer Therapeutics,
|x 2196-5501 ;
|v 18
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-319-78238-6
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 950 |
|
|
|a Biomedical and Life Sciences (Springer-11642)
|
